Section ofNeurology 981 slightly more distally but does not reach the junction with the sensory root. Infiltration of the cerebral parenchyma is rare and in my experience is confined to lymphosarcoma, if primary reticulosis of the brain (microgliomatosis) is excluded. It may occur in conjunction with meningeal infiltration or independently. It may be either perivascular or diffuse even in the same case (Fig 3) . It involves various parts of the brain at random: cortex, white matter, basal ganglia, brain stem (Fig 4) and cerebellum.
Infiltration of peripheral nerves is also rare, occurs in lymphosarcoma (Henson & Urich 1970) and has been reported in other lymphomas (Barron et al. 1960) . The peripheral nerves are infiltrated over long stretches in a random fashion. By contrast with meningeal infiltration the dorsal root ganglia may be involved ( Fig 5) .
Of the cranial nerves, infiltration of the nerves of external ocular movements in the orbit deserves mention ( Fig 6) .
Clinically cases with diffuse infiltration may present with progressive dementia, focal neurological deficit, signs of raised intracranial pressure or peripheral neuropathy. Those with a central presentation may be difficult to distinguish from progressive multifocal leuco-encephalopathy, the peripheral ones from paraneoplastic neuropathies. In the latter case involvement of cranial nerves, particularly the III, IV and VI, favours infiltration. The diagnosis of involvement is now aided by the Cytocentrifuge (Shandon Instruments) which allows concentration of cells on a microscope slide with excellent preservation of morphology.
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A new preparation of methotrexate, Methotrexate I.T., is now available for intrathecal use in the treatment of meningeal involvement by leukemia or lymphoma. It is hoped that this will lessen the side effects of the drug. Cytosine arabinoside is effective given intrathecally: it must be diluted with sterile water containing no preservative. The drugs are probably best given not in combination but as twice-weekly methotrexate for five injections followed by cytosine arabinoside at the same time intervals. Dr Arthur Jones (Department ofRadiotherapy, St Bartholomew's Hospital, London ECJ) Radiotherapy Tumours of the lymphoreticular system are as a group the most responsive of the conditions amenable to therapeutic irradiation. Judged by the rate at which a mass shrinks after exposure to a given dose of radiation, or by the ease with which a focal aggregation of cells may be sterilized, this group is of high radiosensitivity. This has two valuable consequences. First, even when the neoplastic manifestations are extensive, useful tumour regressions may be obtained with relief of symptoms. Secondly, it is becoming increasingly recognized that local cure of the disease may be obtained within a treated volume, by dosage within the tolerance of normal tissue. This important aspect has in the past been obscured by the high propensity of certain types for diffuse metastasis, and by the seemingly multicentric origin of others. In the case of Hodgkin's disease the great advances in treatment have come from differentiating histological types, from delineating distinct patterns of spread so that meaningful staging could be applied, and from recognizing that adequate radiation dosage when given to well-defined volumes of tissue which encompassed the tumour process could result in prolonged survival amounting in many cases to cure. The importance of detailed investigation, including lymphangiography and often laparotomy, now needs no emphasis (Kaplan 1972a , b, Smithers 1972 , 1973 . The best treatment for Hodgkin's disease in Stages I and
